Catalyst
Slingshot members are tracking this event:
FDA Confirms Design of Phase 3 Trial Evaluating Esperion's (ESPR) Bempedoic Acid for Lowering Low Density Lipoprotein Cholesterol (LDL-C)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ESPR |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 20, 2017
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Fda, Phase 3, Bempedoic Acid, Low Density Lipoprotein Cholesterol, Ldl-c
